Arcus Biosciences, Inc. (RCUS) Earnings Call Analysis
NYSE · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Arcus Biosciences (RCUS) Q1 2026: R&D Spend Down 10% as Castatafan Drives $5B+ RCC Ambition
June 16, 2026
-
Arcus Biosciences (RCUS) Q4 2025: Castatafan ORR Rises to 45%, Sharpening RCC Leadership Ambition
June 15, 2026
-
Arcus Biosciences (RCUS) Q1 2025: $1B Cash Position Extends Runway Through Three Pivotal Readouts
July 07, 2025